POWELL MICHAEL 4

What Happened Michael Powell, a director of Bicara Therapeutics, received a grant/award on 2026-06-09 covering 19,475 shares reported as a derivative acquisition at $0.00. The filing classifies this as an award (transaction code A), not an open-market purchase or sale, so no cash changed hands and no shares were sold.

Key Details

• Transaction date: 2026-06-09; Form 4 filed 2026-06-10 (appears timely).
• Reported transaction: 19,475 shares; reported acquisition price $0.00; transaction type = Award/Grant (derivative).
• Shares owned after transaction: not specified in the provided filing excerpt.
• Footnote: The underlying shares vest upon the earlier of (i) June 9, 2027 or (ii) the date of the next annual meeting of stockholders, and only if Powell remains in service on the vesting date.
• No indication of a cashless exercise, sale, tax withholding, 10b5-1 plan, or that Powell is a 10% owner.

Context This was a derivative grant (an award that typically converts to actual shares only upon vesting or exercise). Such awards are common compensation for directors and do not represent an immediate market purchase or sale—therefore they are not a direct liquidity signal. Retail investors should note the vesting conditions and timing (by mid‑2027 or sooner at the next annual meeting) to understand when these shares could potentially be issued or exercised.